Key result
PCSK9 mAb initiation linked to ~53% drop in background statin dispensing at 12 months.
Why the study?
Does initiation of PCSK9 monoclonal antibodies affect adherence to background oral lipid-lowering therapy in high-risk patients?
Cohort (n=4,784)
Yes
Does initiation of PCSK9 monoclonal antibodies affect adherence to background oral lipid-lowering therapy in high-risk patients?
Answers are grounded in this paper and cite their sources.
Initiation of PCSK9 monoclonal antibodies is associated with a concerning and significant discontinuation of background oral lipid-lowering therapies like statins and ezetimibe.
AIMS: Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) are recommended for high-risk patients if the low-density lipoprotein cholesterol targets are not achieved with statins and ezetimibe. We studied persistence and adherence to (i) PCSK9 mAbs and (ii) statins and ezetimibe in a nationwide cohort of incident PCSK9 mAb users. METHODS AND RESULTS: Information on all PCSK9 mAb users ≤80 years from 2015 through 2023 were extracted from the Norwegian Drug Registry. Discontinuation was defined as a gap in treatment ≥180 days and ≥90 days. Adherence was measured as the proportion of days covered during the initial year of PCSK9 mAb therapy. We analysed adherence of statins and ezetimibe before and after PCSK9 mAb initiation. Of 4784 patients initiating PCSK9 mAbs, the median age was 63 years, 41% were female, 61% had atherosclerotic disease, and 34% had familial hypercholesterolaemia. Within 3 years after initiation, 17% experienced a PCSK9 mAb treatment gap exceeding 180 days. In the 12-month period preceding PCSK9 mAb initiation, 74% dispensed statins whereas 67% dispensed ezetimibe. These numbers were reduced to 35% for statins and 42% for ezetimibe during the 12-month period after PCSK9 mAb initiation. Atherosclerotic disease, using ≥3 statins previously, and older age were significantly associated with discontinuation of statins and ezetimibe. CONCLUSION: In this high-risk cohort of incident PCSK9 mAb users, more than 1 out of 2 stopped taking statin treatment whereas 40% discontinued ezetimibe. There is a major potential for improving adherence to oral LLD treatment following initiation of PCSK9 mAb.
No takes yet. Share an insight, caveat, or question.
Engebretsen et al. (2024) conducted a cohort in High cardiovascular risk (atherosclerotic disease or familial hypercholesterolaemia) (n=4,784). PCSK9 monoclonal antibodies vs. 12-month period preceding PCSK9 mAb initiation was evaluated on Dispensing of statins during the 12-month period after PCSK9 mAb initiation. Initiation of PCSK9 monoclonal antibodies was associated with a reduction in statin dispensing from 74% to 35% and ezetimibe dispensing from 67% to 42% in the subsequent 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: